The Healthcare ETF Showdown: Broad Global Health or Targeted Pharma Power?
PJP delivered 32.8% returns over one year with concentrated U.S. pharma exposure, while IXJ offers broader global healthcare diversification and a higher dividend yield.
Choosing between Invesco Pharmaceuticals ETF (PJP) and iShares Global Healthcare ETF (IXJ) requires weighing divergent approaches to the healthcare sector. While both fund types belong to the healthcare sector, their focus on U.S. drugmakers versus an expansive global healthcare perspective yields distinct risk profiles. One offers concentration in domestic drug development, whereas the other promises a broader view of the worldwide medical economy.
The iShares Global Healthcare ETF (IXJ) demonstrates greater cost efficiency with a lower expense ratio of 0.38%, compared to the higher 0.58% expense ratio of Invesco Pharmaceuticals ETF (PJP). Moreover, IXJ offers a higher dividend yield - 1.3% compared to PJP's 0.9%. This yield advantage positions IXJ as the more attractive option for investors seeking income.
IXJ extends its reach across the global healthcare landscape, holding more than 100 stocks, and is heavily weighted towards the U.S. market at 73%. Its top holdings include pharmaceutical giants like Eli Lilly, Johnson & Johnson, and AbbVie. Conversely, PJP is more narrowly focused on the U.S. pharmaceutical industry, investing in 28 stocks and also featuring industry leaders such as AbbVie, Pfizer, and Gilead Sciences.
Historically, PJP has delivered a higher total return of 66% since 2021, with a strong CAGR of 10.7%. In contrast, IXJ generated a modester return of 39% during the same period, with a slightly lower CAGR of 6.8%.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
